Radiotherapy Market is expected to grow at a CAGR of 5.4% during the forecasted period | Evolve Business Intelligence

As per the study initiated by Evolve Business Intelligence, the global Radiotherapy Market size accounted for USD 6.5 Billion in 2022, growing at a CAGR of 5.4% from 2023 to 2033. Radiotherapy Market refers to the business and economic aspects related to the development, production, distribution, and utilization of radiotherapy technologies and services. Radiotherapy, also known as radiation therapy, is a medical treatment that uses high doses of radiation to target and kill cancer cells. It plays a crucial role in the management of various types of cancers.The radiotherapy market encompasses a range of products and services, including radiation therapy equipment, such as linear accelerators and brachytherapy devices, as well as associated accessories and software.
Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021348
The Radiotherapy Market is characterized by the presence of various companies that manufacture and provide radiotherapy equipment, along with research and development activities aimed at improving treatment efficacy and reducing side effects. Market dynamics may also be influenced by factors such as regulatory requirements, reimbursement policies, and the overall healthcare infrastructure in different regions.
Key Players
Some of the major Radiotherapy Market players holding high market shares include R. Bard Inc., Elekta, Hitachi Ltd., IBA SA and Isoray Medical Inc. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Becton Dickinson and Company, Ion Beam Appications SA, Eckert & Zeigler Group and Accuray.
Report Description: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021348

Segmental Analysis
Based on Type, the Radiotherapy Market is segmented into Systematic radiation therapy, internal radiation therapy and External beam radiation therapy. The external beam radiation therapy dominated the market. EBRT's ability to provide precise and accurate doses of radiation to the target tissue while minimizing exposure to healthy tissue is driving the market growth of radiotherapy. The increasing incidence of cancer and rising demand for advanced treatments also contribute to the market's growth.
Based on Application, the Radiotherapy Market is segmented into Skin and lip cancer, Head and neck cancer, Breast cancer, Prostate cancer and cervical cancer. The breast cancer segment dominated the market growth. This is due to the rise in the incidence of breast cancer and the increase in the demand of radiotherapy in the treatment of breast cancer is predicted to drive market growth.
Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune's global 2000 companies.

This release was published on openPR.